OOIR: Observatory of International Research

Papers

(The TQCC of Pharmacoeconomics is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018)	443
How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment	139
The Growing Burden of Major Depressive Disorders (MDD): Implications for Researchers and Policy Makers	68
What are the Economic Costs to Society Attributable to Alcohol Use? A Systematic Review and Modelling Study	65
Estimating the Relationship Between EQ-5D-5L and EQ-5D-3L: Results from a UK Population Study	52
Common Problems, Common Data Model Solutions: Evidence Generation for Health Technology Assessment	50
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations	48
The Use of a Discrete Choice Experiment Including Both Duration and Dead for the Development of an EQ-5D-5L Value Set for Australia	48
EQ-5D-Y Value Set for Slovenia	47
Systematic Review of Conceptual, Age, Measurement and Valuation Considerations for Generic Multidimensional Childhood Patient-Reported Outcome Measures	41
Economic Burden of Multiple Sclerosis in Low- and Middle‐Income Countries: A Systematic Review	38
Economic Evaluation of Digital Health Interventions: Methodological Issues and Recommendations for Practice	37
Global Economic Burden of Attention-Deficit/Hyperactivity Disorder: A Systematic Review	35
Valuation of SF-6Dv2 Health States in China Using Time Trade-off and Discrete-Choice Experiment with a Duration Dimension	34
Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel	32
Productivity-Adjusted Life-Years: A New Metric for Quantifying Disease Burden	29
Best–Worst Scaling and the Prioritization of Objects in Health: A Systematic Review	28
Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine	27
Health State Utilities of Patients with Heart Failure: A Systematic Literature Review	26
Are We Agreed? Self- Versus Proxy-Reporting of Paediatric Health-Related Quality of Life (HRQoL) Using Generic Preference-Based Measures: A Systematic Review and Meta-Analysis	26
Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China	24
Overlap of Depressive Symptoms with Health-Related Quality-of-Life Measures	23
Putting Stakeholder Engagement at the Center of Health Economic Modeling for Health Technology Assessment in the United States	23
The Economic Burden of Non-Alcoholic Steatohepatitis: A Systematic Review	23
Evaluating the Individual Healthcare Costs and Burden of Disease Associated with RSV Across Age Groups	23

Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective	23
The Application and Implications of Novel Deterministic Sensitivity Analysis Methods	21
The Potential Value-Based Price of a Multi-Cancer Early Detection Genomic Blood Test to Complement Current Single Cancer Screening in the USA	21
EQ-5D-Y Value Set for Germany	20
Use of Productivity Loss/Gain in Cost-Effectiveness Analyses for Drugs: A Systematic Review	20
Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological Considerations from Country-Level Estimates	20
A Comparison of PROPr and EQ-5D-5L Value Sets	20
Cost-Effectiveness of Erenumab for the Preventive Treatment of Migraine in Patients with Prior Treatment Failures in Sweden	20
Economic Implications of Endometriosis: A Review	19
Estimating an EQ-5D-Y-3L Value Set for China	19
Estimation of an EORTC QLU-C10 Value Set for Spain Using a Discrete Choice Experiment	19
Value Set for the EQ-5D-Y-3L in Hungary	18
Developing the EQ-5D-5L Value Set for Uganda Using the ‘Lite’ Protocol	18
The Challenges of Outcomes-Based Contract Implementation for Medicines in Europe	18
Incorporating Equity Concerns in Cost-Effectiveness Analyses: A Systematic Literature Review	17
Circulating Tumour DNA as a Potential Cost-Effective Biomarker to Reduce Adjuvant Chemotherapy Overtreatment in Stage II Colorectal Cancer	17
Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US	17
What Did Time Tell Us? A Comparison and Retrospective Validation of Different Survival Extrapolation Methods for Immuno-Oncologic Therapy in Advanced or Metastatic Renal Cell Carcinoma	17
Productivity of Working at Home and Time Allocation Between Paid Work, Unpaid Work and Leisure Activities During a Pandemic	16
A Value Set for the EQ-5D-Y-3L in the Netherlands	16
The Challenges of Measuring Informal Care Time: A Review of the Literature	15
Cost-Effectiveness Analysis of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) for the Primary Staging of Prostate Cancer in Australia	15
Economic Burden of Treatment-Resistant Depression among Adults with Chronic Non-Cancer Pain Conditions and Major Depressive Disorder in the US	15
Economic Impact of Insufficient and Disturbed Sleep in the Workplace	15
Impact of Influenza and Influenza-Like Illness on Work Productivity Outcomes: A Systematic Literature Review	15
A Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine	15
Modifying NICE’s Approach to Equity Weighting	15
Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer	15
Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review	15
The Costs of Dementia in Europe: An Updated Review and Meta-analysis	15
Production Losses due to Absenteeism and Presenteeism: The Influence of Compensation Mechanisms and Multiplier Effects	14
Preference Elicitation Techniques Used in Valuing Children’s Health-Related Quality-of-Life: A Systematic Review	14
The EQ-5D-5L Valuation Study in Egypt	14
Resource Utilization of Patients with Parkinson’s Disease in the Late Stages of the Disease in Germany: Data from the CLaSP Study	14
The Increasing Economic Burden with Additional Steps of Pharmacotherapy in Major Depressive Disorder	13
Patient Preferences in Targeted Pharmacotherapy for Cancers: A Systematic Review of Discrete Choice Experiments	13
Health Economists on Involving Patients in Modeling: Potential Benefits, Harms, and Variables of Interest	13
Deprescribing Interventions among Community-Dwelling Older Adults: A Systematic Review of Economic Evaluations	13
Multiple Myeloma in Portugal: Burden of Disease and Cost of Illness	13
Carers’ Health-Related Quality of Life in Global Health Technology Assessment: Guidance, Case Studies and Recommendations	12
Direct Medical Costs, Productivity Loss Costs and Out-Of-Pocket Expenditures in Women with Breast Cancer in Latin America and the Caribbean: A Systematic Review	12
The Societal Cost of Schizophrenia: An Updated Systematic Review of Cost-of-Illness Studies	12
Systematic Literature Review to Assess the Cost and Resource Use Associated with Spinal Muscular Atrophy Management	12
Aspects and Challenges of Resource Use Measurement in Health Economics: Towards a Comprehensive Measurement Framework	12
Valuing the Quality-of-Life Aged Care Consumers (QOL-ACC) Instrument for Quality Assessment and Economic Evaluation	12
Using a Modified Delphi Approach to Gain Consensus on Relevant Comparators in a Cost-Effectiveness Model: Application to Prostate Cancer Screening	12
Cost-Effectiveness and Economic Impact of Bladder Cancer Management: An Updated Review of the Literature	11
Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial)	11
Living Health Technology Assessment: Issues, Challenges and Opportunities	11
Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA)	11

Cost Effectiveness Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review	11
Methodological Challenges in the Economic Evaluation of a Gene Therapy for RPE65-Mediated Inherited Retinal Disease: The Value of Vision	11
Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA	10
Do Costs in the Education Sector Matter? A Systematic Literature Review of the Economic Impact of Psychosocial Problems on the Education Sector	10
Disease-Related Costs Published in The Middle East and North Africa Region: Systematic Review and Analysis of Transferability	10
A Systematic Review of the Methodologies and Modelling Approaches Used to Generate International EQ-5D-5L Value Sets	10
Assessment of the Effects of Active Immunisation against Respiratory Syncytial Virus (RSV) using Decision-Analytic Models: A Systematic Review with a Focus on Vaccination Strategies, Modelling Methods	9
The Excess Costs of Depression and the Influence of Sociodemographic and Socioeconomic Factors: Results from the German Health Interview and Examination Survey for Adults (DEGS)	9
Cluster Analysis of Care Pathways in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior in the USA	9
Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition	9
The Use of Cost-Effectiveness Analysis in Sickle Cell Disease: A Critical Review of the Literature	9
Systematic Literature Review to Identify Utility Values in Patients with Spinal Muscular Atrophy (SMA) and Their Caregivers	9
Principles of Economic Evaluation in a Pandemic Setting: An Expert Panel Discussion on Value Assessment During the Coronavirus Disease 2019 Pandemic	9
Economic Analyses of Respiratory Tract Infection Diagnostics: A Systematic Review	9
Estimation of Transition Probabilities for State-Transition Models: A Review of NICE Appraisals	9
Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study	9
Target Trial Emulation for Transparent and Robust Estimation of Treatment Effects for Health Technology Assessment Using Real-World Data: Opportunities and Challenges	9
Estimating an EQ-5D-Y-3L Value Set for Indonesia by Mapping the DCE onto TTO Values	8
A General Public Study on Preferences and Welfare Impacts of Antimicrobial Resistance in the United Kingdom	8
Role of Economic Evaluations on Pricing of Medicines Reimbursed by the Italian National Health Service	8
Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial	8
Economic Evidence on Potentially Curative Gene Therapy Products: A Systematic Literature Review	8
Cost-effectiveness Analysis of Tisagenlecleucel Versus Blinatumomab in Children and Young Adults with Acute Lymphoblastic Leukemia: Partitioned Survival Model to Assess the Impact of an Outcome-Based	8
Collaborating with Patient Partners to Model Clinical Care Pathways in Major Depressive Disorder: The Benefits of Mixing Evidence and Lived Experience	8
Current Practices for Accounting for Preference Heterogeneity in Health-Related Discrete Choice Experiments: A Systematic Review	8
The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson’s Disease in England	8
The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden	8
Prediction Models for Individual-Level Healthcare Costs Associated with Cardiovascular Events in the UK	8
Caregiver Burden of Spinal Muscular Atrophy: A Systematic Review	8
Health Economic Evaluation Using Markov Models in R for Microsoft Excel Users: A Tutorial	8
Health-Economic Analyses of Diagnostics: Guidance on Design and Reporting	8
Postnatal Major Depressive Disorder in Australia: Inequalities and Costs of Healthcare to Individuals, Governments and Insurers	8
Assessments of the Value of New Interventions Should Include Health Equity Impact	8
RETRACTED ARTICLE: The EQ-5D-5L Valuation Study in Egypt	8
How are Child-Specific Utility Instruments Used in Decision Making in Australia? A Review of Pharmaceutical Benefits Advisory Committee Public Summary Documents	8
A Comparison of the SF-6Dv2 and SF-6D UK Utility Values in a Mixed Patient and Healthy Population	8
In a Child’s Shoes: Composite Time Trade-Off Valuations for EQ-5D-Y-3L with Different Proxy Perspectives	8
Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland	8
Health Economic Evidence and Modeling Challenges for Liquid Biopsy Assays in Cancer Management: A Systematic Literature Review	7
Is an Orphan Drug’s Cost-Effectiveness Associated with US Health Plan Coverage Restrictiveness?	7
Real-World Treatment Costs and Care Utilization in Patients with Major Depressive Disorder With and Without Psychiatric Comorbidities in Specialist Mental Healthcare	7
An EQ-5D-Y-3L Value Set for Belgium	7
Patient and Public Involvement in Health Economics Modelling Raises the Need for Normative Guidance	7
Conceptualising ‘Benefits Beyond Health’ in the Context of the Quality-Adjusted Life-Year: A Critical Interpretive Synthesis	7
Exploring the Issues of Valuing Child and Adolescent Health States Using a Mixed Sample of Adolescents and Adults	7
Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada	7
Associating Health-Related Quality-of-Life Score with Time Uses to Inform Productivity Measures in Cost-Effectiveness Analysis	7
Four Aspects Affecting Health Economic Decision Models and Their Validation	7
Health Economic Research Assessing the Value of Early Detection of Cardiovascular Disease: A Systematic Review	7
EQ-5D-Y Population Norms for Japanese Children and Adolescents	7